

Appl. No. 10/082,691  
Reply to Office action of January 30, 2004

### Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

#### Listing of Claims

1. (Currently amended) A method for treating neurogenic inflammation pain, the method comprises administering ~~an effective amount of a composition which comprises a~~ therapeutically effective amount of an agent to a patient, the agent comprising a botulinum toxin component conjugated with a substance P component, a botulinum toxin component and a substance P component to a patient, thereby treating the neurogenic inflammation pain for at least about two months.

2. (Original) The method of claim 1 wherein the botulinum toxin component comprises an L chain or an HN and an L chain.

3. (Original) The method of claim 2 wherein the HN is obtained from a botulinum toxin selected from the group consisting of botulinum toxin serotype A, serotype B, serotype C, serotype D, serotype E, serotype F and serotype G.

4. (Original) The method of claim 2 wherein the HN is obtained from botulinum toxin serotype A.

5. (Original) The method of claim 2 wherein the L chain is obtained from a botulinum toxin selected from the group

Appl. No. 10/082,691  
Reply to Office action of January 30, 2004

consisting of botulinum toxin serotype A, serotype B, serotype C, serotype D, serotype E, serotype F and serotype G.

6. (Original) The method of claim 2 wherein the L chain is obtained from botulinum toxin serotype A.

7. (Currently amended) The method of claim 1 wherein the substance P component is [[a]] substance P.

8. (Currently amended) The method of claim 1 wherein the substance P component is a precursor of substance P having an amino acid sequence selected from the group of consisting of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, and SEQ ID NO: 10.

9. (Currently amended) The method of claim 1 wherein the substance P component is a substance P functional analogue.

10. (Withdrawn) The method of claim 1 wherein the pain is selected from the group consisting of fibromyalgia pain.

11. (Withdrawn) The method of claim 1 wherein the pain is myofascial pain syndrome pain.

12. (Original) The method of claim 1 wherein the pain is arthritis pain.

13. (Withdrawn) The method of claim 1 wherein the pain is migraine headache pain.

Appl. No. 10/082,691

Reply to Office action of January 30, 2004

14. (Withdrawn) The method of claim 1 wherein the pain is irritable bowel syndrome pain.

15. (Withdrawn) The method of claim 1 wherein the pain is Crohn's disease pain.

16. (Withdrawn) The method of claim 1 wherein the pain is interstitial cystitis pain.

17. (Currently amended) The method of claim 1 wherein the ~~composition~~ agent is administered subcutaneously.

18. (Currently amended) The method of claim 1 wherein the ~~composition~~ agent is administered intramuscularly.

19. (Currently amended) The method of claim 1 wherein the ~~composition~~ agent is administered systemically.

20. (Withdrawn) The method of claim 14 wherein the composition is administered with a needle.

21. (Withdrawn) The method of claim 14 wherein the composition is administered by needleless injection.

22. (Currently amended) The method of claim 1 wherein the agent ~~contains the botulinum neurotoxin component~~ is administered in an amount that will reduce pain in a patient by about 20% as determined by the patient based on a pain quantification scale.

Appl. No. 10/082,691  
Reply to Office action of January 30, 2004

23. (Currently amended) The method of claim 1 wherein the agent ~~contains the botulinum neurotoxin component~~ is administered in an amount that will reduce pain in a patient by about 40% as determined by the patient based on a pain quantification scale.

24. (Currently amended) The method of claim 1 wherein the agent ~~contains the botulinum neurotoxin component~~ is administered in an amount that will reduce pain in a patient by about 50% as determined by the patient based on a pain quantification scale.

25. (Currently amended) The method of claim 1 wherein the agent ~~contains the botulinum neurotoxin component~~ is administered in an amount that will reduce pain in a patient by about 60% as determined by the patient based on a pain quantification scale.

26. (Currently amended) The method of claim 1 wherein the agent ~~contains the botulinum neurotoxin component~~ is administered in an amount that will reduce pain in a patient by about 80% as determined by the patient based on a pain quantification scale.

27. (Currently amended) The method of claim 1 wherein the agent ~~contains the botulinum neurotoxin component~~ is administered in an amount that will reduce pain in a patient by about 100% as determined by the patient based on a pain quantification scale.

Appl. No. 10/082,691  
Reply to Office action of January 30, 2004

28. (Withdrawn) A method for inhibiting pain caused by degranulation of mast cells wherein the method comprises administering to a patient an effective amount of a composition which comprises a botulinum toxin component attached to a substance P component, thereby inhibiting degranulation of mast cells.

29. (Withdrawn) A method for inhibiting pain caused by degranulation of mast cells and release of inflammation mediating compounds from vascular endothelial cells wherein the method comprises administering to a patient an effective amount of a composition which comprises a botulinum toxin component attached to a substance P component, thereby inhibiting pain caused by degranulation of mast cells and release of inflammation mediating compounds from vascular endothelial cells.